Table 3 Baseline characteristics
From: Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis
Trial | Aetiology of respiratory failurea | Treatment group | Age (years) | Initial PaO2/FiO2 | PRISM score | |
|---|---|---|---|---|---|---|
Luchetti, 1998 | Bronchiolitis Pneumonia | 100% | Surfactant | 0.87 (0.15) | 118 (15.8) | Not reported |
| Â | Â | 50% | Placebo | 0.93 (0.17) | 122 (12.0) | Not reported |
Willson, 1999 | ARDS | 31% | Â | Â | Â | Â |
| Â | Pneumonia | 26% | Surfactant | 5.0 (5.34) | 102 (53) | 12 (6) |
| Â | RSV | 17% | Placebo | 4.5 (5.66) | 105 (42) | 9 (4) |
| Â | Near-drowning | 7% | Â | Â | Â | Â |
| Â | Sepsis | 7% | Â | Â | Â | Â |
| Â | Other | 14% | Â | Â | Â | Â |
Tibby, 2000 | RSV | 100% | Surfactant | 0.17 (0.14, 0.27)b | 146 (134, 171)b | 11 (11, 15)b |
| Â | Â | Â | Placebo | 0.13 (0.09, 0.18)b | 160 (106, 205)b | 13 (11, 15)b |
Luchetti, 2002 | RSV | 100% | Surfactant | 0.73 (0.675) | Not reported | 12 (1.1) |
| Â | Pneumonia | 45% | Placebo | 0.62 (0.542) | Not reported | 12 (1.2) |
Moller, 2003 | Pneumonia | 68% | Surfactant | 3.5 (range 0–13) | 71 (13.7) | 12 (6.5) |
|  | Sepsis | 32% | Placebo | 4.5 (range (0–12) | 64 (16.2) | 11 (4.5) |
Willson, 2005 | ARDS or sepsis | 35% | Surfactant | 7.2 (6.4) | 128 (54) | 15 (9.4) |
| Â | Pneumonia | 42% | Placebo | 6.7 (6.4) | 126 (73) | 14 (7.9) |
| Â | RSV | 7% | Â | Â | Â | Â |
| Â | Near-drowning | 5% | Â | Â | Â | Â |
| Â | Other | 11% | Â | Â | Â | Â |